Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 1, 2023
Daily News
November 1, 2023
- Daiichi Sankyo to Merge 2 Subsidiaries to Enhance ADC Production
November 1, 2023
- Organization to Push Drug Discovery Is One Option: Health Minister
November 1, 2023
- Otsuka Files Rexulti for Alzheimer’s Associated Agitation in Japan
November 1, 2023
- Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
- Otsuka Calls Off PIII Bipolar Trial for SEP-4199 on Stalled Recruitment
November 1, 2023
- Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products
November 1, 2023
- Basic Dementia Law Set to Take Effect on January 1: MHLW
November 1, 2023
- Idorsia Files Insomnia Med Daridorexant in Japan: Sosei, Mochida
November 1, 2023
- Japan Economic Package to Call for Boosting Innovation for Next-Gen Biologics
November 1, 2023
- Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
November 1, 2023
- 301 Employees Apply for Shionogi’s Voluntary Buyout Program
November 1, 2023
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…